Sep 26, 2022CSL Receives Manufacturing and Marketing Authorization in Japan for “Berinert® S.C. Injection 2000,” as a Medicine for prevention of Acute Hereditary Angioedema (HAE) attacks
CSL Behring K.K. (Head Office: Minato-ku, Tokyo; President and Representative Director: Jean-Marc Morange) announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert® S.C. Injection 2000,” a lyophilized human C1-esterase inhibitor concentrate...
Sep 19, 2022
CSL applauds the United States District Court’s decision to issue a preliminary injunction preventing the United States Customs and Border Protection (CBP) from continuing to enforce its ban on plasma donations by Mexican nationals who enter the U.S. on a B-1/B-2 visa.
Sep 8, 2022Orphan Drug Designation granted for etranacogene dezaparvovec, CSL’s gene therapy for haemophilia B, by the Therapeutics Goods Administration
TGA’s designation underscores CSL’s promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions
Aug 17, 2022CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
KING OF PRUSSIA, PA CSL is on track to file for regulatory approvals next year and will present full data set at an upcoming scientific congress 17 Aug 2022 Global biotechnology leader CSL...
- Jun 24, 2022CSL continues to provide medicines to patients around the world.
CSL continues to provide medicines to patients around the world. 24 Jun 2022 Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues...
- Jun 9, 2022Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
Rankin's first in-person U.S. exhibit in three years showcases portraits and personal stories highlighting the remarkable progress made in understanding and treating hemophilia and hopes for the future
May 24, 2022FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CSL Behring's promise to develop and deliver a...
Apr 28, 2022CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorders
The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access...
Mar 28, 2022European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with...
- Mar 2, 2022With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors
Forbes Magazine has named global biotechnology leader CSL among America's Best Employers for 2022. The annual rankings from Forbes and Statista, the world-leading statistics portal and industry...
Feb 4, 2022Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022- Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy
Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational...
Jan 18, 2022CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.Ad hoc release pursuant to Art. 53 LR, Switzerland
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender...
Dec 15, 2021CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
KING OF PRUSSIA, PA, USA – DECEMBER 15, 2021 – Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific...
Dec 9, 2021uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec
Lexington, MA and Amsterdam, the Netherlands, King of Prussia, PA , December 9, 2021 — CSL Behring, a global biotherapeutics leader, and uniQure N.V. (NASDAQ: QURE), a leading gene therapy...
Oct 19, 2021Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day• CSL advances novel pipeline spanning six therapeutic areas, four scientific platforms and two businesses (CSL Behring and Seqirus)
MELBOURNE, AU and KING OF PRUSSIA, PA; October 19/18, 2021 – During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel...
Oct 5, 2021CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion.
CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion. 05 Oct 2021 Global biotech leader CSL has...
Sep 17, 2021Here's how CSL is working around the world with academia, industry and governments to combat COVID-19
CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...
- Sep 11, 2021Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership Development, Workforce Diversity and Job Creation and Training.
Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership...
Aug 9, 2021The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance TreatmentThe updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients
The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients 09 Aug 2021 KING OF PRUSSIA, Pa. – Aug. 9, 2021 – Global...
Aug 3, 2021FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient ConvenienceApproval received to co-package a convenience administration kit along with the product BERINERT.
KING OF PRUSSIA, PA 03 Aug 2021 CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for...
Jun 8, 2021Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP PatientsHizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home
KING OF PRUSSIA, Pa. 08 Jun 2021 Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare...
Jun 2, 2021CSL continues to provide medicines to patients around the world.
Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new...
May 16, 2021New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 DaysFindings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period
KING OF PRUSSIA, Pa. 16 May 2021 Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more...
May 13, 2021Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award
NEW YORK, NY, USA – May 13, 2021 – Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a...
May 6, 2021CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
KING OF PRUSSIA, PA, USA – MAY 6, 2021 – Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) for